Atlas Venture Raises $400 Million for Start-Up Funding

In a hopeful sign for the biotech industry, Cambridge-based VC firm Atlas Venture has raised $400 million in an oversubscribed fundraiser for its third Opportunity Fund III which equips Atlas to continue providing funding to its portfolio companies as they advance their therapeutic programs. The raise comes on the heels of Atlas’ $450 million Fund XIV, its latest early stage vehicle which closed in December 2024.

According to the firm’s website, Atlas’ two-fund model is powered by dedicated pools of early stage and growth capital for Atlas to invest in portfolio companies with promising therapeutic programs and pipelines. Beginning with seed and Series A investments from the early-stage funds, the Atlas investment team collaborates with entrepreneurs-in-residence to form and incubate new biotech companies around promising science sourced from around the globe. (Source: Atlas Venture Website, 02 September, 2025)